| Identification | More | [Name]
Tegaserod | [CAS]
145158-71-0 | [Synonyms]
2-[(5-methoxy-1h-indol-3-yl)methylene]-n-pentylhydrazine-carboximidamide
TEGASEROD
Tegaserode | [Molecular Formula]
C16H23N5O | [MDL Number]
MFCD06660144 | [Molecular Weight]
301.39 | [MOL File]
145158-71-0.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S36/37:Wear suitable protective clothing and gloves .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . |
| Hazard Information | Back Directory | [Uses]
Treatment of gastrointestinal motility disorders
(selective serotonin 5HT4antagonist). | [Definition]
ChEBI:Tegaserod is a member of guanidines, a carboxamidine, a member of hydrazines and a member of indoles. It has a role as a serotonergic agonist and a gastrointestinal drug. | [Indications]
Tegaserod (Zelnorm) is serotonin-4 (5-HT4) receptor agonists that stimulate GI motility. | [Brand name]
Zelmac (Novartis). | [Clinical Use]
Tegaserod is being developed as a treatment for constipation-
predominant irritable bowel syndrome (IBS).
Within the first week, patients treated with tegaserod
had significant improvements in abdominal pain and discomfort,
constipation, and overall well-being. Efficacy
was maintained throughout the treatment period.
Tegaserod also demonstrated significant improvements
in the three bowel-related assessments (stool frequency,
stool consistency, and straining) within the first week,
and these improvements were sustained throughout the
treatment period. The most common adverse events reported
thus far are headache and diarrhea.
|
|
|